Premium
Elevation of plasminogen activator inhibitor 1 in borderline hypertension is linked to concomitant metabolic disturbances
Author(s) -
LEMNE C.,
FAIRE U. DE
Publication year - 1996
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.1996.tb02155.x
Subject(s) - medicine , endocrinology , fibrinogen , blood pressure , plasminogen activator , plasminogen activator inhibitor 1 , body mass index , concomitant , von willebrand factor , essential hypertension , insulin , platelet
. In the present study we investigated plasma levels of plasminogen activator inhibitor 1 (PAI‐1), fibrinogen and von Willebrand factor (vWF) in borderline hypertensive (BHT) men [diastolic blood pressure (DBP) 85–94 mmHg, n = 75] and age‐matched normotensive (NT) control subjects (DBP ≤80 mmHg, n = 75), in relation to smoking, body mass index (BMI) and fasting lipoprotein and insulin levels. PAI‐1 levels were elevated in the BHT group [16.3 vs. 13.7 arbitrary units (AU), P = 0.032], whereas levels of fibrinogen and vWF were similar in the two groups. The PAI‐1 elevation was even more pronounced in dyslipidaemic BHT subjects than in normolipidaemic NT subjects (20.0 vs. 10.3 arbitrary units (AU), P = 0.001). PAI‐1 levels showed strong correlations with insulin, lipoproteins and BMI ( P < 0.01‐0.001), but not with DBP. The results show that disturbances in the fibrinolytic system appear even in borderline hypertension. The elevation of PAI‐1 levels seems to be more strongly linked to concomitant metabolic disturbances than to blood pressure levels.